LABP vs. MNOV, CKPT, LTRN, LVTX, DERM, RLYB, VHAQ, MRNS, LPTX, and TPST
Should you be buying Landos Biopharma stock or one of its competitors? The main competitors of Landos Biopharma include MediciNova (MNOV), Checkpoint Therapeutics (CKPT), Lantern Pharma (LTRN), LAVA Therapeutics (LVTX), Journey Medical (DERM), Rallybio (RLYB), Viveon Health Acquisition (VHAQ), Marinus Pharmaceuticals (MRNS), Leap Therapeutics (LPTX), and Tempest Therapeutics (TPST). These companies are all part of the "pharmaceutical preparations" industry.
Landos Biopharma (NASDAQ:LABP) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, community ranking, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.
MediciNova has lower revenue, but higher earnings than Landos Biopharma. MediciNova is trading at a lower price-to-earnings ratio than Landos Biopharma, indicating that it is currently the more affordable of the two stocks.
Landos Biopharma has a beta of 0.14, suggesting that its stock price is 86% less volatile than the S&P 500. Comparatively, MediciNova has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.
Landos Biopharma currently has a consensus price target of $20.42, suggesting a potential downside of 10.95%. Given Landos Biopharma's higher probable upside, equities research analysts clearly believe Landos Biopharma is more favorable than MediciNova.
MediciNova received 179 more outperform votes than Landos Biopharma when rated by MarketBeat users. However, 62.50% of users gave Landos Biopharma an outperform vote while only 51.86% of users gave MediciNova an outperform vote.
MediciNova's return on equity of -13.35% beat Landos Biopharma's return on equity.
49.1% of Landos Biopharma shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 1.3% of Landos Biopharma shares are held by company insiders. Comparatively, 14.9% of MediciNova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, MediciNova had 1 more articles in the media than Landos Biopharma. MarketBeat recorded 6 mentions for MediciNova and 5 mentions for Landos Biopharma. MediciNova's average media sentiment score of 0.79 beat Landos Biopharma's score of 0.75 indicating that MediciNova is being referred to more favorably in the news media.
Summary
MediciNova beats Landos Biopharma on 10 of the 15 factors compared between the two stocks.
Get Landos Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LABP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LABP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Landos Biopharma Competitors List
Related Companies and Tools
